1 Day
Source:
المشهد العربي
Novo Nordisk shares fall before patent expiry
Shares of Danish company Novo Nordisk fell by as much as 9% due to tensions and reports regarding its pricing strategies and merger and acquisition plans, especially as the patents for some of its key drugs, such as Semaglutide used for obesity and diabetes, are nearing expiration. The company had reaffirmed during events in London its plans to launch more than five new drugs by 2030 and to achieve revenues exceeding 150 billion Danish kroner (approximately $23 billion) by 2035. This decline comes amid fierce competition with American company Eli Lilly, which expects its drug Zepbound sales to surpass Wegoofy by more than $7 billion this year.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)